Nilai Dipunlarasaken Utang lan Kas: Akero Therapeutics (AKRO)

Tandha merek Akero Corp (AKRO)

Akero Therapeutics' efficiency relies on the success of Efruxifermin testing, the control of development costs, and strategic alliances. This chart of the company's valuation history is currently at 3762.12. The business focuses on creating innovative treatments for liver pathologies, where the ability to stop fibrosis could secure leadership in the premium medical segment.

Nilai Total Perusahaan akerotx.com (AKRO): kanggo periode 23.11.2025 - 20.12.2025

Akero Therapeutics (AKRO) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Rega saham Akero Therapeutics, Inc.|AKRO - Bagan rega target
- indikator kapitalisasi bursa perusahaan:
Nilai pasar Akero Therapeutics|AKRO - Nilai Total Perusahaan
- informasi kapitalisasi buku:
Nilai Aset Bersih saben Saham Akero Therapeutics|AKRO - Nilai Buku Perusahaan|Kapitalisasi Pasar marang Aset Bersih akerotx.com|AKRO - Total Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Rasio Kabeh Utang marang Dana Pribadi Akero Therapeutics|AKRO - Utang jangka dawa marang modal|Utang jangka cendhak marang modal akerotx.com|AKRO - Utang perusahaan|Rasio utang marang aset resik Akero Therapeutics|AKRO - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Akero Therapeutics|Rasio cepet akerotx.com
- rincian bathi lan kelipatan pasar:
AKRO - Penghasilan resik
Analisis kabeh metrik perusahaan:Akero Therapeutics, Inc.
Produk merek Akero Therapeutics

The resilience of Akero Therapeutics (AKRO) to market volatility depends directly on the development costs of efruxifermin and the prospects of FDA approval. By analyzing changes in Enterprise Value (EV), an investor can determine the actual acquisition price of the business via the sum of market capitalization and net debt, allowing for an assessment of the company's fundamental value without the distortions typical of simple share prices.

Pesaing Akero Therapeutics (AKRO)

Nilai Perusahaan Ascendis Pharma AS ASND|MDGL - Nilai Total Perusahaan|Nilai Dipunlarasaken Utang lan Kas CORT (Corcept Therapeutics Corp)|Rhythm Pharmaceuticals (RYTM) - Nilai Total Perusahaan|Total Nilai Perusahaan metsera.com (MTSR)|Nilai Total Perusahaan MoonLake|Crinetics Pharmaceuticals, Inc. - Nilai Wutuh Bisnis|Nilai Perusahaan NAMS|SLNO (Soleno Therapeutics Corp) - Nilai Dipunlarasaken Utang lan Kas|Nilai Perusahaan FOLD (Amicus Therapeutics)|Nilai Perusahaan 89bio.com ETNB|AGIO - Nilai Total Perusahaan|Nilai Dipunlarasaken Utang lan Kas GPCR (Structure Therapeutics Inc)|MiMedx Group (MDXG) - Nilai Total Perusahaan|Rega Nyata Tumbas Perusahaan Kanthi Wutuh Rezolute Bio|LXRX (Lexicon Pharmaceuticals) - Nilai Perusahaan|Nilai Perusahaan mbxbio.com|Rega Nyata Tumbas Perusahaan Kanthi Wutuh ALT (Altimmune)|AARD (Aardvark Therapeutics Inc.) - Nilai Dipunlarasaken Utang lan Kas|Nilai Total Perusahaan Sagimet SGMT|BIOA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh|Biomea Fusion, Inc. - Nilai Perusahaan|Total Nilai Perusahaan Quince Therapeutics|GUTS (Fractyl Health) - Rega Nyata Tumbas Perusahaan Kanthi Wutuh|VTVT: Total Nilai Bisnis|ATPC (Agape ATP Corp) - Nilai Perusahaan|Nilai Perusahaan Pluri Inc|Nilai Perusahaan SYBX|Nilai Total Perusahaan LPCN (lipocine.com)|Nilai Total Perusahaan Matinas BioPharma Holdings MTNB|sprucebiosciences.com (SPRB) - Total Nilai Perusahaan|GLTO - Nilai Total Perusahaan|CTCX: Nilai Total Perusahaan|LUMO: Nilai Perusahaan|ONVO - Rega Tumbas Perusahaan|Nilai Total Perusahaan Radius Recycling